Serum Levels of Angiotensin Converting Enzyme in Systemic Lupus Erythematous Patients
NCT ID: NCT05516511
Last Updated: 2022-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
75 participants
OBSERVATIONAL
2023-01-31
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Angiotensin II and strong candidate for a mediator of the development and progression of renal disease in SLE has been found to promote glomerular cell proliferation, alter growth factor expression, and activate proinflammatory cytokines, all of which promote glomerulosclerosis
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients
NCT05964751
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
NCT06631404
Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
NCT03958851
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
NCT07144514
AntiDFS70 Lupus Nephritis
NCT06119763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cases
systemic lupus erythematosus patients
Angiotensin Converting Enzyme test
blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
control
healthy individuals
Angiotensin Converting Enzyme test
blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Angiotensin Converting Enzyme test
blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
17 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yasmin Abdelfattah Mohamed
resident doctor at Physical medicine,Rheumatolgy and Rehabilitaion Department , Faculty of medicine, Sohag University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University Hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Mohamed A Ismail, assisstant professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
osama R Elsherief, professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 Feb;39(4):257-68. doi: 10.1016/j.semarthrit.2008.10.007. Epub 2009 Jan 10.
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb;65(2):521-30. doi: 10.1111/j.1523-1755.2004.00443.x.
Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006 Jan;21(1):16-20. doi: 10.1093/ndt/gfi265. Epub 2005 Nov 9.
Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000 Apr;75:S7-14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-22-08-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.